Predictive Oncology Return on Tangible Equity 2011-2025 | POAI
Current and historical return on tangible equity values for Predictive Oncology (POAI) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Predictive Oncology Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2025-06-30 | $-0.01B | $0.00B | 0.00% |
| 2025-03-31 | $-0.01B | $0.00B | -666.67% |
| 2024-12-31 | $-0.01B | $0.00B | -480.00% |
| 2024-09-30 | $-0.01B | $0.00B | -288.89% |
| 2024-06-30 | $-0.01B | $0.00B | -192.59% |
| 2024-03-31 | $-0.01B | $0.00B | -151.35% |
| 2023-12-31 | $-0.01B | $0.01B | -101.96% |
| 2023-09-30 | $-0.02B | $0.01B | -110.77% |
| 2023-06-30 | $-0.02B | $0.01B | -95.00% |
| 2023-03-31 | $-0.03B | $0.02B | -104.17% |
| 2022-12-31 | $-0.03B | $0.02B | -96.15% |
| 2022-09-30 | $-0.03B | $0.03B | -90.09% |
| 2022-06-30 | $-0.03B | $0.03B | -80.00% |
| 2022-03-31 | $-0.02B | $0.03B | -51.70% |
| 2021-12-31 | $-0.02B | $0.03B | -53.33% |
| 2021-09-30 | $-0.02B | $0.05B | -78.63% |
| 2021-06-30 | $-0.03B | $0.05B | -147.06% |
| 2021-03-31 | $-0.03B | $0.03B | -800.00% |
| 2020-12-31 | $-0.03B | $0.00B | 432.00% |
| 2020-09-30 | $-0.03B | $0.00B | 413.79% |
| 2020-06-30 | $-0.03B | $-0.01B | 327.27% |
| 2020-03-31 | $-0.02B | $-0.01B | 283.87% |
| 2019-12-31 | $-0.02B | $-0.01B | 347.83% |
| 2019-09-30 | $-0.01B | $-0.01B | 225.00% |
| 2019-06-30 | $-0.01B | $-0.01B | 533.33% |
| 2019-03-31 | $-0.01B | $0.00B | -1466.67% |
| 2018-12-31 | $-0.01B | $0.00B | -444.44% |
| 2018-09-30 | $-0.01B | $0.00B | -246.15% |
| 2018-06-30 | $-0.01B | $0.00B | -184.62% |
| 2018-03-31 | $-0.01B | $0.01B | -215.38% |
| 2017-12-31 | $-0.01B | $0.00B | -200.00% |
| 2017-09-30 | $-0.01B | $0.00B | -240.00% |
| 2017-06-30 | $-0.01B | $0.00B | -300.00% |
| 2017-03-31 | $-0.01B | $0.00B | -400.00% |
| 2016-12-31 | $-0.01B | $0.00B | -700.00% |
| 2016-09-30 | $-0.01B | $0.00B | -457.14% |
| 2016-06-30 | $-0.01B | $0.00B | -246.15% |
| 2016-03-31 | $-0.01B | $0.00B | -400.00% |
| 2015-12-31 | $0.00B | $0.00B | 800.00% |
| 2015-09-30 | $0.00B | $0.01B | 133.33% |
| 2015-06-30 | $0.00B | $-0.01B | 72.73% |
| 2015-03-31 | $-0.01B | $-0.01B | 105.26% |
| 2014-12-31 | $-0.01B | $-0.01B | 186.67% |
| 2014-09-30 | $-0.01B | $0.00B | 233.33% |
| 2014-06-30 | $-0.01B | $0.00B | 444.44% |
| 2014-03-31 | $-0.01B | $0.00B | 360.00% |
| 2013-12-31 | $-0.01B | $0.00B | 327.27% |
| 2013-09-30 | $-0.01B | $0.00B | 327.27% |
| 2013-06-30 | $-0.01B | $0.00B | 266.67% |
| 2013-03-31 | $-0.01B | $0.00B | 360.00% |
| 2012-12-31 | $-0.01B | $0.00B | 320.00% |
| 2012-09-30 | $-0.01B | $0.00B | 360.00% |
| 2012-06-30 | $-0.01B | $0.00B | 254.55% |
| 2012-03-31 | $-0.01B | $0.00B | 166.67% |
| 2011-12-31 | $0.00B | $0.00B | 145.45% |
| 2011-09-30 | $0.00B | $0.00B | 40.00% |
| 2011-06-30 | $0.00B | $0.00B | 0.00% |
| 2011-03-31 | $0.00B | $0.00B | 0.00% |
| 2010-12-31 | $0.00B | $0.00B | 44.44% |
| 2010-09-30 | $0.00B | $0.00B | 44.44% |
| 2010-06-30 | $0.00B | $0.00B | 88.89% |
| 2010-03-31 | $0.00B | $0.00B | 171.43% |
| 2009-12-31 | $0.00B | $0.00B | 300.00% |
| 2009-06-30 | $0.00B | 0.00% | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.027B | $0.002B |
| Predictive Oncology Inc. is focused on applying artificial intelligence to personalized medicine and drug discovery. Its operating business unit consists of Helomics, TumorGenesis and Skyline Medical. Predictive Oncology Inc., formerly known as Precision Therapeutics Inc., is based in MINNEAPOLIS. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $47.732B | 58.24 |
| Tempus AI (TEM) | United States | $12.524B | 0.00 |
| Doximity (DOCS) | United States | $11.721B | 48.51 |
| Hims & Hers Health (HIMS) | United States | $9.384B | 76.89 |
| IRhythm Technologies (IRTC) | United States | $5.716B | 0.00 |
| Hinge Health (HNGE) | United States | $3.454B | 0.00 |
| Privia Health (PRVA) | United States | $2.943B | 184.46 |
| Heartflow (HTFL) | United States | $2.876B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $2.435B | 40.29 |
| Enovis (ENOV) | United States | $1.624B | 8.53 |
| 10x Genomics (TXG) | United States | $1.618B | 0.00 |
| Omnicell (OMCL) | United States | $1.605B | 32.81 |
| Schrodinger (SDGR) | United States | $1.373B | 0.00 |
| Azenta (AZTA) | United States | $1.355B | 59.10 |
| Clover Health Investments (CLOV) | United States | $1.338B | 0.00 |
| Phreesia (PHR) | United States | $1.334B | 0.00 |
| Claritev (CTEV) | United States | $1.021B | 0.00 |
| Evolent Health (EVH) | United States | $0.705B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.683B | 0.00 |
| Talkspace (TALK) | United States | $0.568B | 113.00 |
| Butterfly Network (BFLY) | United States | $0.566B | 0.00 |
| Veradigm (MDRX) | United States | $0.545B | 0.00 |
| Standard BioTools (LAB) | United States | $0.431B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.402B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.320B | 0.00 |
| Carlsmed (CARL) | United States | $0.316B | 0.00 |
| TruBridge (TBRG) | United States | $0.289B | 13.27 |
| CapsoVision (CV) | United States | $0.225B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.220B | 0.00 |
| Outset Medical (OM) | United States | $0.210B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.208B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.186B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.183B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.171B | 0.00 |
| CareCloud (CCLD) | United States | $0.147B | 8.07 |
| EUDA Health Holdings (EUDA) | Singapore | $0.112B | 0.00 |
| NetraMark Holdings (AINMF) | Canada | $0.077B | 0.00 |
| Pulmonx (LUNG) | United States | $0.074B | 0.00 |
| American Well (AMWL) | United States | $0.066B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.058B | 0.00 |
| HeartBeam (BEAT) | United States | $0.056B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.040B | 0.00 |
| 111 (YI) | China | $0.037B | 0.00 |
| Precipio (PRPO) | United States | $0.033B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.024B | 0.00 |
| Zhongchao (ZCMD) | China | $0.018B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.016B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.010B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.009B | 0.00 |
| PROFUSA (PFSA) | United States | $0.008B | 0.00 |
| HeartSciences (HSCS) | United States | $0.007B | 0.00 |
| Movano (MOVE) | United States | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.002B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.001B | 0.00 |